<DOC>
	<DOCNO>NCT02182024</DOCNO>
	<brief_summary>To assess effect different degree renal impairment pharmacokinetics pharmacodynamics dabigatran etexilate administer orally .</brief_summary>
	<brief_title>Pharmacokinetics , Pharmacodynamics , Safety Tolerability Dabigatran Etexilate Patients With Without Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Healthy male female subject determine result screen creatinine clearance &gt; 80 mL/min ( group 1 , control group ) Renally impaired male female subject determine result screen follow creatinine clearance result : creatinine clearance &gt; 50 ≤80 mL/min ( group 2 ) creatinine clearance &gt; 30 ≤50 mL/min ( group 3 ) creatinine clearance ≤30 mL/min ( group 4 ) uraemia require maintenance dialysis ( group 5 ) Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Age &gt; =18 &lt; =75 year BMI &gt; =18.0 &lt; =32 kg/m2 , least 45 kg female Any find medical examination ( include blood pressure , pulse rate , electrocardiogram ) deviate normal clinical relevance Clinically relevant gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic hormonal disorder Surgery gastrointestinal tract ( except appendectomy , cholecystectomy herniotomy ) Clinically relevant diseases central nervous system Relevant history orthostatic hypotension , faint spell blackouts Abnormal prothrombin time ( PT ) , TT , aPTT ( must within normal range one repeat test ) , thrombocytes &lt; 150000/μl ( two repeat first test ) Evidence haematuria either macroscopically detectable microscopic urinalysis ( normal microscopic result one repeated test ) Evidence blood dyscrasia , haemorrhagic diathesis , severe thrombocytopenia , cerebrovascular haemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition haemorrhagic tendency ( e.g . cerebral aneurysm , dissect aorta , central nervous system ( CNS ) trauma , retinopathy nephrolithiasis ) Recent contemplate diagnostic therapeutic procedure potential uncontrollable bleeding ( e.g . spinal puncture , lumbar block anaesthesia , surgery CNS eye surgery result large open surface ) within 14 day drug administration clinical trial Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator For woman childbearing potential : reliable contraception ( accept method intra uterine device , hormonal contraceptive , bilateral tubal ligation , hysterectomy , condom ) pregnancy ( know detect positive pregnancy test ) breast feeding period Intake drug long halflife ( &gt; 24 hour ) ( &lt; 1 month prior administration trial ) Use drug , within 14 day prior administration trial Participation another trial investigational drug ( &lt; 2 month prior drug administration trial ) Drug abuse Blood donation loss &gt; 400 mL , &lt; 1 month prior administration trial Excessive physical activity &lt; 5 day prior administration study drug trial Clinically relevant laboratory abnormality Renally impaired subject ( group 2 , 3 , 4 5 ) meet follow criterion enter trial : Moderate severe concurrent liver function impairment ( e.g . due hepatorenal syndrome ) Clinically relevant gastrointestinal , respiratory , cardiovascular , metabolic , immunologic hormonal disorder Surgery gastrointestinal tract ( except appendectomy , cholecystectomy herniotomy ) Clinically relevant diseases central nervous system Relevant history orthostatic hypotension , faint spell blackouts Abnormal value PT , TT , aPTT thrombocyte consider investigator one coinvestigators clinically relevant Evidence blood dyscrasia , haemorrhagic diathesis , severe thrombocytopenia , cerebrovascular haemorrhage , bleed tendency associate active ulceration overt bleed gastrointestinal , respiratory genitourinary tract disease condition haemorrhagic tendency ( e.g . cerebral aneurysm , dissect aorta , CNS trauma , retinopathy , nephrolithiasis ) consider investigator one coinvestigators clinically relevant Recent contemplate diagnostic therapeutic procedure potential uncontrollable bleeding ( e.g . spinal puncture , lumbar block anaesthesia , surgery CNS eye surgery result large open surface ) within 14 day drug administration clinical trial Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator For woman childbearing potential : reliable contraception ( accept method intrauterine device , hormonal contraceptive , bilateral tubal ligation , hysterectomy condom ) pregnancy ( know detect positive pregnancy test ) breastfeeding period Participation another trial investigational drug ( &lt; 2 month prior administration trial ) Drug abuse Blood donation loss &gt; 400 mL , &lt; 1 month prior administration trial Excessive physical activity &lt; 5 day prior administration study drug trial Clinically relevant laboratory abnormality except value typical renally impaired patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>